Previously acquired AveXis renamed as Novartis Gene Therapies... Sep 04
Medicines will be sold at zero-profit to governments in up to 791 eligible countries during the pandemic and until a vaccine or curative treatment ... Jul 17
AveXis, which makes Novartis’s $2.1 million-per-patient gene therapy Zolgensma for the hereditary disease spinal muscular atrophy, is contributing technology, expertise and ... May 29
-Advertisements-
.jpeg)
Sunday, November 24, 2024
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)